# EDGAR Filing Document

**Accession Number:** 0002011674
**File Stem:** 0000000000-25-007084
**Filing Date:** 2025-7
**Character Count:** 4852
**Document Hash:** 96b3b9d1abf04223b9de6eed34e13f17
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007084.hdr.sgml**: 20251121

**ACCESSION NUMBER**: 0000000000-25-007084

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250703

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** YD Bio Ltd
- **CENTRAL INDEX KEY:** 0002011674
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-283428

**BUSINESS ADDRESS:**
- **STREET 1:** 955 WEST JOHN CARPENTER FREEWAY
- **STREET 2:** SUITE 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039
- **BUSINESS PHONE:** 619-500-7747

**MAIL ADDRESS:**
- **STREET 1:** 955 WEST JOHN CARPENTER FREEWAY
- **STREET 2:** SUITE 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** True Velocity, Inc./DE
- **DATE OF NAME CHANGE:** 20240209
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-24-101742

## Text-Extract

```

                                                            July 3, 2025

J. Douglas Ramsey, Ph.D
Chief Executive Officer
YD Bio Limited
955 West John Carpenter Freeway
Suite 100-929
Irving, TX, 75039

Ethan Shen, Ph.D
Chief Executive Officer
YD Biopharma Limited
12F., No. 3, Xingnan St.
Nangang Dist.
Taipei City 115001, Taiwan

       Re: YD Bio Limited
           Amendment No. 7 to Registration Statement on Form F-4
           Filed June 30, 2025
           File No. 333-283428
Dear J. Douglas Ramsey Ph.D and Ethan Shen Ph.D:

     We have reviewed your amended registration statement and have the
following
comment(s).

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments. Unless
we note
otherwise, any references to prior comments are to comments in our June 18,
2025 letter.
 July 3, 2025
Page 2
Amendment No. 7 to Form F-4, Filed June 30, 2025
Exhibits

1.     We note the following opinion in Exhibit 8.1: "Based on and subject to
the foregoing,
       including, without limitation, the qualifications, exceptions and
assumptions set forth
       above and the exceptions, qualifications and limitations set forth
below, in our opinion
       . . . (ii) the statements of United States federal income tax law with
respect to the
       Parent Merger on the date hereof, or the holding or disposition of Pubco
shares
       received in connection with the Parent Merger, as set forth in the
Registration
       Statement under the caption "Material U.S. Federal Income Tax
Considerations," are
       accurate in all material respects," and a similar opinion appears in
Exhibit 8.2: "Based
       on and subject to the foregoing, the qualifications, exceptions,
assumptions,
       qualifications and limitations contained herein and in the Registration
Statement, it is
       our opinion that . . . (ii) the statements in the Registration Statement
set forth under
       the caption "Material U.S. Federal Income Tax Considerations," to the
extent that
       they constitute descriptions or summaries of material U.S. federal
income tax
       considerations attributable to the Merger or to the holding or
disposition of Pubco
       shares received in connection with the Merger, are accurate in all
material
       respects." The "fairness" or "accuracy" of the prospectus disclosure is
not the
       appropriate subject of the opinion. Counsel must opine on the tax
consequences of the
       offering, not the manner in which they are described in the prospectus.
Refer to
       Section III.C.2 of Staff Legal Bulletin No. 19.
       Please contact Christie Wong at 202-551-3684 or Michael Fay at
202-551-3812 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jane Park at 202-551-7439 or Margaret Sawicki at 202-551-7153 with any
other
questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of
Industrial Applications and
                                                            Services
cc:   Mathew J. Saur, Esq.
      Marc Rivera, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._